{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=104", "query": { "intervention": "serum sample", "page": 104 }, "page_size": 10 }, "pagination": { "page": 104, "page_size": 10, "total_count": 8383, "total_pages": 839, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=105&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=103&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-08T12:42:07.490Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04570839", "title": "COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Endometrial Neoplasms", "Ovarian Cancer", "Solid Tumor", "Head and Neck Cancer" ], "interventions": [ { "name": "COM701 in combination with BMS-986207 and nivolumab.", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Compugen Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2020-08-31", "completion_date": "2024-05-15", "has_results": false, "last_update_posted_date": "2024-07-18", "last_synced_at": "2026-11-08T12:42:07.490Z", "location_count": 9, "location_summary": "Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 6 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04570839" }, { "nct_id": "NCT00356122", "title": "Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2006-07", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2011-10-17", "last_synced_at": "2026-11-08T12:42:07.490Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00356122" }, { "nct_id": "NCT01407237", "title": "Physiologic Investigation of the Renin Angiotensin Aldosterone Axis in HIV", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV-infection" ], "interventions": [ { "name": "Angiotensin II Infusion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2012-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-08-05", "last_synced_at": "2026-11-08T12:42:07.490Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01407237" }, { "nct_id": "NCT02576145", "title": "A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Kidney Transplantation" ], "interventions": [ { "name": "DT", "type": "BIOLOGICAL" }, { "name": "Daclizumab", "type": "DRUG" }, { "name": "KLH", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "19 Years", "sex": "ALL", "summary": "2 Years to 19 Years" }, "enrollment_count": 11, "start_date": "2003-04", "completion_date": "2006-01", "has_results": true, "last_update_posted_date": "2016-01-13", "last_synced_at": "2026-11-08T12:42:07.490Z", "location_count": 5, "location_summary": "Los Angeles, California • Indianapolis, Indiana • Kansas City, Missouri + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02576145" }, { "nct_id": "NCT06091254", "title": "A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Follicular Lymphoma (FL)" ], "interventions": [ { "name": "Odronextamab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone/prednisolone", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 822, "start_date": "2023-12-12", "completion_date": "2029-11-03", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-11-08T12:42:07.490Z", "location_count": 20, "location_summary": "Tucson, Arizona • Los Angeles, California • Orange, California + 17 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Noblesville", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06091254" }, { "nct_id": "NCT06448754", "title": "Volrustomig Priming Regimens Exploratory Phase II Platform Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Volrustomig", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 194, "start_date": "2024-08-27", "completion_date": "2027-07-30", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-11-08T12:42:07.490Z", "location_count": 2, "location_summary": "Los Angeles, California • Chapel Hill, North Carolina", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06448754" }, { "nct_id": "NCT01121939", "title": "Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroendocrine Carcinoma" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Sandostatin LAR® Depot", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2010-05", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2016-02-05", "last_synced_at": "2026-11-08T12:42:07.490Z", "location_count": 9, "location_summary": "Fort Myers, Florida • Orlando, Florida • Augusta, Georgia + 6 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01121939" }, { "nct_id": "NCT00377572", "title": "Inner-City Anti-IgE Therapy for Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "omalizumab", "type": "BIOLOGICAL" }, { "name": "omalizumab placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "20 Years", "sex": "ALL", "summary": "6 Years to 20 Years" }, "enrollment_count": 419, "start_date": "2006-10", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2017-03-21", "last_synced_at": "2026-11-08T12:42:07.490Z", "location_count": 8, "location_summary": "Tucson, Arizona • Denver, Colorado • Washington D.C., District of Columbia + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00377572" }, { "nct_id": "NCT01133665", "title": "Cetuximab and Lenalidomide in Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma" ], "interventions": [ { "name": "Cetuximab and Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2010-02", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2014-11-24", "last_synced_at": "2026-11-08T12:42:07.490Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01133665" }, { "nct_id": "NCT00168753", "title": "Community Based Trial for AMEVIVE®", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Moderate to Severe Chronic Plaque Psoriasis" ], "interventions": [ { "name": "Alefacept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 114, "start_date": "2004-07", "completion_date": "2005-03", "has_results": false, "last_update_posted_date": "2014-09-08", "last_synced_at": "2026-11-08T12:42:07.490Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Anchorage, Alaska + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Bakersfield", "state": "California" }, { "city": "Riverside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00168753" } ] }